These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11233805)

  • 1. The role of lomefloxacin in the treatment of chronic prostatitis.
    Scelzi S; Travaglini F; Nerozzi S; Dominici A; Ponchietti R; Novelli A; Rizzo M
    J Chemother; 2001 Feb; 13(1):82-7. PubMed ID: 11233805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostatic tissue and fluid levels of lomefloxacin (NY-198)].
    Nasu Y; Nishitani Y; Yamada D; Hayata S; Tsugawa M; Kishi M; Mizuno A; Kumon H; Ohmori H; Nanba K
    Hinyokika Kiyo; 1989 Mar; 35(3):551-6. PubMed ID: 2735259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lemofloxacin: antimicrobial ability and clinico-pharmacokinetic basis for use in urogenital infections].
    Iakovlev SV
    Urologiia; 2002; (1):11-4. PubMed ID: 11877963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis.
    Dorfman M; Barsanti J; Budsberg SC
    Am J Vet Res; 1995 Mar; 56(3):386-90. PubMed ID: 7771709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lomefloxacin concentration in human prostatic tissue following 3-day administration].
    Morita M; Hatakeyama T; Suzuki K
    Hinyokika Kiyo; 1993 Jan; 39(1):97-9. PubMed ID: 7681621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of lomefloxacin into human prostatic tissue.
    Leroy A; Humbert G; Fillastre JP; Grise P
    Am J Med; 1992 Apr; 92(4A):12S-14S. PubMed ID: 1374582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
    Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
    J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraprostatic distribution of lomefloxacin following multiple-dose administration.
    Kovarik JM; de Hond JA; Hoepelman IM; Boon T; Verhoef J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2398-401. PubMed ID: 2088193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
    Suzuki K; Horiba M; Naide Y; Shinoda M; Hibi H
    Hinyokika Kiyo; 1992 Jan; 38(1):121-8. PubMed ID: 1312292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study.
    Cazzola M; Matera MG; Tufano MA; Catalanotti P; Polverino M; Cantoni V; Fici F; Sarlo F; Rossi F
    J Chemother; 2001 Aug; 13(4):407-12. PubMed ID: 11589484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of rufloxacin into human prostatic tissue and fluid.
    Boerema JB; Bach D; Jol C; Pahlmann W
    J Antimicrob Chemother; 1991 Oct; 28(4):547-54. PubMed ID: 1662190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.
    Drusano GL; Preston SL; Van Guilder M; North D; Gombert M; Oefelein M; Boccumini L; Weisinger B; Corrado M; Kahn J
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2046-51. PubMed ID: 10898674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.
    Kovarik JM; Hoepelman AI; Smit JM; Sips PA; Rozenberg-Arska M; Glerum JH; Verhoef J
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2458-61. PubMed ID: 1336948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of prostatic adenoma with concomitant chronic bacterial prostatitis].
    Davidov MI
    Urologiia; 2011; (1):21-8. PubMed ID: 21500490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of temafloxacin in the treatment of chronic bacterial prostatitis.
    Naber KG; Boerema JB; Bischoff W; Blenk H; Focht J; Carpentier P; Sylvester J
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():87-96. PubMed ID: 1664834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of temafloxacin into body tissues and fluids.
    Sörgel F
    Clin Pharmacokinet; 1992; 22 Suppl 1():57-63. PubMed ID: 1319872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration.
    Bergogne-Bérézin E; Muller-Serieys C; Kafé H
    Am J Med; 1992 Apr; 92(4A):8S-11S. PubMed ID: 1316076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Typhoid fevers: treatment with lomefloxacin.
    Hafiz S; Habib F; Ahmad N; Haq I; Husain R
    J Pak Med Assoc; 1998 Jun; 48(6):168-70. PubMed ID: 9813988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
    Stone JW; Andrews JM; Ashby JP; Griggs D; Wise R
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1508-10. PubMed ID: 3190181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration.
    Baldwin DR; Wise R; Andrews JM; Gill M; Honeybourne D
    Respir Med; 1993 Nov; 87(8):595-601. PubMed ID: 8290743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.